CleftGeneDB-Search

Gene: SPRY2

Basic information

Tag	Content
Uniprot ID	O43597; B2R9J9; Q5T6Z7;
Entrez ID	10253
Genbank protein ID	AAH15745.1; BAG36546.1; CAD28524.1; AAC04258.1;
Genbank nucleotide ID	NM_001318538.1; NM_001318537.1; NM_001318536.1; NM_005842.3;
Ensembl protein ID	ENSP00000366308; ENSP00000366306;
Ensembl nucleotide ID	ENSG00000136158
Gene name	Protein sprouty homolog 2
Gene symbol	SPRY2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2 (By similarity). Thereby acts as an antagonist of FGF-induced retinal lens fiber differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis (By similarity). Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells (By similarity).
Sequence	MEARAQSGNG SQPLLQTPRD GGRQRGEPDP RDALTQQVHV LSLDQIRAIR NTNEYTEGPT 60 VVPRPGLKPA PRPSTQHKHE RLHGLPEHRQ PPRLQHSQVH SSARAPLSRS ISTVSSGSRS 120 STRTSTSSSS SEQRLLGSSF SSGPVADGII RVQPKSELKP GELKPLSKED LGLHAYRCED 180 CGKCKCKECT YPRPLPSDWI CDKQCLCSAQ NVIDYGTCVC CVKGLFYHCS NDDEDNCADN 240 PCSCSQSHCC TRWSAMGVMS LFLPCLWCYL PAKGCLKLCQ GCYDRVNRPG CRCKNSNTVC 300 CKVPTVPPRN FEKPT 315

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
3BUM
3OB1
5HKY
5HKZ
5HL0

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	SPRY2	539090	Q08E39			Bos taurus	Prediction	More>>
1:1 ortholog	SPRY2	485504	E2RGU9			Canis lupus familiaris	Prediction	More>>
1:1 ortholog	SPRY2	102188779	A0A452DWT1			Capra hircus	Prediction	More>>
1:1 ortholog	SPRY2		F6UL06			Equus caballus	Prediction	More>>
1:1 ortholog	SPRY2	10253	O43597			Homo sapiens	Prediction	More>>
1:1 ortholog	Spry2	24064	Q9QXV8	CPO	E13.5, E14.5, E16.5	Mus musculus	Publication	More>>
1:1 ortholog	SPRY2		H2Q7P2			Pan troglodytes	Prediction	More>>
1:1 ortholog	SPRY2	100157266	F1RP67			Sus scrofa	Prediction	More>>
1:1 ortholog	SPRY2	100352158	G1SXJ1			Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Spry2	306141	Q5HZA2			Rattus norvegicus	Prediction	More>>
1:1 ortholog	spry2	335098	F1QU39			Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1389050196	p.Glu2Asp	missense variant	-	NC_000013.11:g.80337700C>A	TOPMed,gnomAD
rs1433952843	p.Glu2Lys	missense variant	-	NC_000013.11:g.80337702C>T	gnomAD
rs202021168	p.Ala5Val	missense variant	-	NC_000013.11:g.80337692G>A	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gln6Glu	missense variant	-	NC_000013.11:g.80337690G>C	NCI-TCGA
COSM4414438	p.Gln6Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337689T>C	NCI-TCGA Cosmic
rs1445307159	p.Ser7Ile	missense variant	-	NC_000013.11:g.80337686C>A	gnomAD
rs141948380	p.Ser7Gly	missense variant	-	NC_000013.11:g.80337687T>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ser7GluPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.80337688_80337689insT	NCI-TCGA
rs567043511	p.Asn9Ser	missense variant	-	NC_000013.11:g.80337680T>C	1000Genomes,ExAC,gnomAD
rs771424788	p.Gly10Arg	missense variant	-	NC_000013.11:g.80337678C>G	ExAC,TOPMed,gnomAD
rs771424788	p.Gly10Arg	missense variant	-	NC_000013.11:g.80337678C>T	ExAC,TOPMed,gnomAD
COSM3469869	p.Ser11Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337674G>A	NCI-TCGA Cosmic
rs1184243800	p.Pro13Thr	missense variant	-	NC_000013.11:g.80337669G>T	TOPMed
rs1012981412	p.Gln16Glu	missense variant	-	NC_000013.11:g.80337660G>C	TOPMed,gnomAD
rs372480996	p.Thr17Met	missense variant	-	NC_000013.11:g.80337656G>A	ESP,ExAC,TOPMed,gnomAD
rs774765586	p.Thr17Ser	missense variant	-	NC_000013.11:g.80337657T>A	gnomAD
rs372480996	p.Thr17Met	missense variant	-	NC_000013.11:g.80337656G>A	NCI-TCGA
rs368770309	p.Arg19Pro	missense variant	-	NC_000013.11:g.80337650C>G	ESP,gnomAD
rs368770309	p.Arg19His	missense variant	-	NC_000013.11:g.80337650C>T	ESP,gnomAD
rs141331436	p.Asp20Ala	missense variant	-	NC_000013.11:g.80337647T>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1294807470	p.Asp20Asn	missense variant	-	NC_000013.11:g.80337648C>T	gnomAD
rs1326668831	p.Gly21Ser	missense variant	-	NC_000013.11:g.80337645C>T	gnomAD
rs767200640	p.Arg25Ser	missense variant	-	NC_000013.11:g.80337633G>T	ExAC,gnomAD
rs757245505	p.Arg25His	missense variant	-	NC_000013.11:g.80337632C>T	ExAC,TOPMed,gnomAD
rs767200640	p.Arg25Gly	missense variant	-	NC_000013.11:g.80337633G>C	ExAC,gnomAD
rs1434458506	p.Gly26Arg	missense variant	-	NC_000013.11:g.80337630C>T	TOPMed
rs1389822163	p.Glu27Gln	missense variant	-	NC_000013.11:g.80337627C>G	gnomAD
rs751596093	p.Asp29Asn	missense variant	-	NC_000013.11:g.80337621C>T	ExAC,gnomAD
rs1174893630	p.Pro30Thr	missense variant	-	NC_000013.11:g.80337618G>T	TOPMed
rs1449032625	p.Arg31Lys	missense variant	-	NC_000013.11:g.80337614C>T	gnomAD
rs762829116	p.Arg31Gly	missense variant	-	NC_000013.11:g.80337615T>C	ExAC,gnomAD
rs771376928	p.Asp32Glu	missense variant	-	NC_000013.11:g.80337610G>T	ExAC,gnomAD
rs759745233	p.Ala33Asp	missense variant	-	NC_000013.11:g.80337608G>T	ExAC,TOPMed,gnomAD
rs759745233	p.Ala33Val	missense variant	-	NC_000013.11:g.80337608G>A	ExAC,TOPMed,gnomAD
rs759745233	p.Ala33Val	missense variant	-	NC_000013.11:g.80337608G>A	NCI-TCGA
rs1223824474	p.Gln37His	missense variant	-	NC_000013.11:g.80337595C>G	gnomAD
rs771050581	p.Val38Leu	missense variant	-	NC_000013.11:g.80337594C>G	ExAC,TOPMed,gnomAD
rs772271382	p.Ser42Pro	missense variant	-	NC_000013.11:g.80337582A>G	ExAC,gnomAD
NCI-TCGA novel	p.Ser42Tyr	missense variant	-	NC_000013.11:g.80337581G>T	NCI-TCGA
rs748556088	p.Gln45Arg	missense variant	-	NC_000013.11:g.80337572T>C	ExAC,gnomAD
rs200366516	p.Gln45His	missense variant	-	NC_000013.11:g.80337571C>A	1000Genomes,ExAC,gnomAD
rs1230673905	p.Ala48Val	missense variant	-	NC_000013.11:g.80337563G>A	TOPMed,gnomAD
COSM697253	p.Ala48Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337563G>C	NCI-TCGA Cosmic
rs755783967	p.Ile49Phe	missense variant	-	NC_000013.11:g.80337561T>A	ExAC,gnomAD
rs200813001	p.Arg50Gln	missense variant	-	NC_000013.11:g.80337557C>T	1000Genomes,ExAC,gnomAD
rs200813001	p.Arg50Gln	missense variant	-	NC_000013.11:g.80337557C>T	NCI-TCGA
COSM948816	p.Arg50Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.80337558G>A	NCI-TCGA Cosmic
rs1345516409	p.Thr52Ala	missense variant	-	NC_000013.11:g.80337552T>C	TOPMed
COSM948815	p.Glu57Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337536T>C	NCI-TCGA Cosmic
COSM4923208	p.Gly58Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337534C>A	NCI-TCGA Cosmic
rs1349891029	p.Pro59Ser	missense variant	-	NC_000013.11:g.80337531G>A	TOPMed
rs138802158	p.Thr60Ala	missense variant	-	NC_000013.11:g.80337528T>C	ESP,gnomAD
COSM76578	p.Val62Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337522C>T	NCI-TCGA Cosmic
rs947314080	p.Arg64Ile	missense variant	-	NC_000013.11:g.80337515C>A	gnomAD
rs947314080	p.Arg64Ile	missense variant	-	NC_000013.11:g.80337515C>A	NCI-TCGA
rs1169840391	p.Gly66Arg	missense variant	-	NC_000013.11:g.80337510C>T	gnomAD
rs369061793	p.Lys68Asn	missense variant	-	NC_000013.11:g.80337502C>A	ESP,ExAC,TOPMed,gnomAD
rs759785348	p.Ala70Thr	missense variant	-	NC_000013.11:g.80337498C>T	ExAC,TOPMed,gnomAD
rs759785348	p.Ala70Pro	missense variant	-	NC_000013.11:g.80337498C>G	ExAC,TOPMed,gnomAD
rs766410528	p.Pro71Leu	missense variant	-	NC_000013.11:g.80337494G>A	ExAC,gnomAD
rs754102296	p.Pro71Ser	missense variant	-	NC_000013.11:g.80337495G>A	ExAC,TOPMed,gnomAD
rs143262252	p.Arg72His	missense variant	-	NC_000013.11:g.80337491C>T	ESP,ExAC,TOPMed,gnomAD
rs773647038	p.Pro73Ala	missense variant	-	NC_000013.11:g.80337489G>C	ExAC,TOPMed,gnomAD
rs1198333643	p.Pro73Leu	missense variant	-	NC_000013.11:g.80337488G>A	gnomAD
rs762291759	p.Ser74Ala	missense variant	-	NC_000013.11:g.80337486A>C	ExAC,gnomAD
rs774762413	p.Thr75Ala	missense variant	-	NC_000013.11:g.80337483T>C	ExAC,gnomAD
rs1326893559	p.Gln76Arg	missense variant	-	NC_000013.11:g.80337479T>C	gnomAD
rs530541115	p.His77Pro	missense variant	-	NC_000013.11:g.80337476T>G	1000Genomes,ExAC,gnomAD
rs530541115	p.His77Arg	missense variant	-	NC_000013.11:g.80337476T>C	1000Genomes,ExAC,gnomAD
rs777215929	p.Glu80Asp	missense variant	-	NC_000013.11:g.80337466C>G	ExAC,gnomAD
rs746523784	p.Glu80Gln	missense variant	-	NC_000013.11:g.80337468C>G	ExAC,TOPMed,gnomAD
rs376920757	p.Arg81Thr	missense variant	-	NC_000013.11:g.80337464C>G	ESP,ExAC,TOPMed,gnomAD
rs376920757	p.Arg81Lys	missense variant	-	NC_000013.11:g.80337464C>T	ESP,ExAC,TOPMed,gnomAD
rs561847010	p.Leu82Pro	missense variant	-	NC_000013.11:g.80337461A>G	1000Genomes,ExAC,gnomAD
rs752628401	p.Leu82Val	missense variant	-	NC_000013.11:g.80337462G>C	ExAC,gnomAD
rs754765201	p.Gly84Arg	missense variant	-	NC_000013.11:g.80337456C>G	ExAC,gnomAD
rs754765201	p.Gly84Ser	missense variant	-	NC_000013.11:g.80337456C>T	ExAC,gnomAD
rs1158468425	p.Pro86Ala	missense variant	-	NC_000013.11:g.80337450G>C	gnomAD
rs1234069800	p.His88Tyr	missense variant	-	NC_000013.11:g.80337444G>A	TOPMed,gnomAD
rs547859496	p.Arg89His	missense variant	-	NC_000013.11:g.80337440C>T	1000Genomes
rs766597189	p.Pro92Ser	missense variant	-	NC_000013.11:g.80337432G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu94Arg	missense variant	-	NC_000013.11:g.80337425A>C	NCI-TCGA
NCI-TCGA novel	p.His96Arg	missense variant	-	NC_000013.11:g.80337419T>C	NCI-TCGA
rs1441415778	p.Ser97Leu	missense variant	-	NC_000013.11:g.80337416G>A	TOPMed,gnomAD
rs1245203690	p.Gln98Pro	missense variant	-	NC_000013.11:g.80337413T>G	gnomAD
rs202166263	p.Gln98Lys	missense variant	-	NC_000013.11:g.80337414G>T	1000Genomes,ExAC,TOPMed
rs762358137	p.His100Tyr	missense variant	-	NC_000013.11:g.80337408G>A	ExAC,gnomAD
rs1337608150	p.Arg104Pro	missense variant	-	NC_000013.11:g.80337395C>G	TOPMed,gnomAD
rs776355694	p.Arg104Gly	missense variant	-	NC_000013.11:g.80337396G>C	ExAC,gnomAD
rs1337608150	p.Arg104Gln	missense variant	-	NC_000013.11:g.80337395C>T	TOPMed,gnomAD
rs770702443	p.Ala105Gly	missense variant	-	NC_000013.11:g.80337392G>C	ExAC,gnomAD
COSM3469868	p.Ala105Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337392G>A	NCI-TCGA Cosmic
rs504122	p.Pro106Ser	missense variant	-	NC_000013.11:g.80337390G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1401740371	p.Pro106Arg	missense variant	-	NC_000013.11:g.80337389G>C	gnomAD
rs504122	p.Pro106Thr	missense variant	-	NC_000013.11:g.80337390G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs504122	p.Pro106Ala	missense variant	-	NC_000013.11:g.80337390G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs771519323	p.Arg109Ser	missense variant	-	NC_000013.11:g.80337379T>A	ExAC,gnomAD
rs748075874	p.Ser110Cys	missense variant	-	NC_000013.11:g.80337377G>C	ExAC,gnomAD
rs754705712	p.Ser112Asn	missense variant	-	NC_000013.11:g.80337371C>T	ExAC,TOPMed,gnomAD
rs754705712	p.Ser112Thr	missense variant	-	NC_000013.11:g.80337371C>G	ExAC,TOPMed,gnomAD
rs61756189	p.Thr113Ala	missense variant	-	NC_000013.11:g.80337369T>C	ESP,ExAC,TOPMed,gnomAD
rs750696145	p.Ser116Leu	missense variant	-	NC_000013.11:g.80337359G>A	ExAC,gnomAD
rs1287620323	p.Gly117Ala	missense variant	-	NC_000013.11:g.80337356C>G	gnomAD
rs867349456	p.Ser118Leu	missense variant	-	NC_000013.11:g.80337353G>A	TOPMed,gnomAD
RCV000207508	p.Arg119Trp	missense variant	IgA nephropathy, susceptibility to, 3 (IGAN3)	NC_000013.11:g.80337351G>A	ClinVar
rs1315863703	p.Arg119Pro	missense variant	-	NC_000013.11:g.80337350C>G	gnomAD
rs1315863703	p.Arg119Gln	missense variant	-	NC_000013.11:g.80337350C>T	gnomAD
rs869025336	p.Arg119Trp	missense variant	-	NC_000013.11:g.80337351G>A	TOPMed,gnomAD
NCI-TCGA novel	p.Arg119Leu	missense variant	-	NC_000013.11:g.80337350C>A	NCI-TCGA
rs1315863703	p.Arg119Gln	missense variant	-	NC_000013.11:g.80337350C>T	NCI-TCGA Cosmic
rs1363308358	p.Ser120Gly	missense variant	-	NC_000013.11:g.80337348T>C	gnomAD
rs1269908375	p.Ser121Thr	missense variant	-	NC_000013.11:g.80337344C>G	gnomAD
rs147789290	p.Thr122Ala	missense variant	-	NC_000013.11:g.80337342T>C	ESP,ExAC,TOPMed,gnomAD
rs752056670	p.Thr122Met	missense variant	-	NC_000013.11:g.80337341G>A	ExAC,gnomAD
rs775982350	p.Arg123Thr	missense variant	-	NC_000013.11:g.80337338C>G	ExAC,gnomAD
rs144291807	p.Arg123Trp	missense variant	-	NC_000013.11:g.80337339T>A	ESP,ExAC,TOPMed,gnomAD
rs775982350	p.Arg123Lys	missense variant	-	NC_000013.11:g.80337338C>T	ExAC,gnomAD
NCI-TCGA novel	p.Arg123Met	missense variant	-	NC_000013.11:g.80337338C>A	NCI-TCGA
rs1312541122	p.Ser127Thr	missense variant	-	NC_000013.11:g.80337326C>G	gnomAD
rs577081286	p.Ser127Arg	missense variant	-	NC_000013.11:g.80337325G>T	1000Genomes
NCI-TCGA novel	p.Ser127Gly	missense variant	-	NC_000013.11:g.80337327T>C	NCI-TCGA
rs772768746	p.Gln133Glu	missense variant	-	NC_000013.11:g.80337309G>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu135Met	missense variant	-	NC_000013.11:g.80337303G>T	NCI-TCGA
rs1373899933	p.Leu136Pro	missense variant	-	NC_000013.11:g.80337299A>G	TOPMed
rs747621224	p.Gly137Glu	missense variant	-	NC_000013.11:g.80337296C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly137Arg	missense variant	-	NC_000013.11:g.80337297C>T	NCI-TCGA
rs1330785319	p.Ser138Ter	stop gained	-	NC_000013.11:g.80337293G>C	TOPMed,gnomAD
rs746584791	p.Phe140Ser	missense variant	-	NC_000013.11:g.80337287A>G	ExAC,TOPMed,gnomAD
rs768580715	p.Ser141Pro	missense variant	-	NC_000013.11:g.80337285A>G	ExAC,TOPMed,gnomAD
rs1291535013	p.Ser141Tyr	missense variant	-	NC_000013.11:g.80337284G>T	TOPMed
rs779805758	p.Ser142Pro	missense variant	-	NC_000013.11:g.80337282A>G	ExAC,gnomAD
NCI-TCGA novel	p.Ser142Phe	missense variant	-	NC_000013.11:g.80337281G>A	NCI-TCGA
rs778275764	p.Gly143Arg	missense variant	-	NC_000013.11:g.80337279C>T	TOPMed,gnomAD
rs778275764	p.Gly143Arg	missense variant	-	NC_000013.11:g.80337279C>G	TOPMed,gnomAD
COSM3885535	p.Pro144Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337276G>A	NCI-TCGA Cosmic
rs146602387	p.Val145Phe	missense variant	-	NC_000013.11:g.80337273C>A	1000Genomes
NCI-TCGA novel	p.Ala146Val	missense variant	-	NC_000013.11:g.80337269G>A	NCI-TCGA
NCI-TCGA novel	p.Ala146Thr	missense variant	-	NC_000013.11:g.80337270C>T	NCI-TCGA
rs904292048	p.Gly148Ser	missense variant	-	NC_000013.11:g.80337264C>T	TOPMed
rs367880580	p.Ile149Val	missense variant	-	NC_000013.11:g.80337261T>C	ESP,ExAC,TOPMed,gnomAD
rs1417193005	p.Ile150Val	missense variant	-	NC_000013.11:g.80337258T>C	TOPMed
rs770217072	p.Arg151Gly	missense variant	-	NC_000013.11:g.80337255G>C	ExAC,TOPMed,gnomAD
rs1167458110	p.Arg151Gln	missense variant	-	NC_000013.11:g.80337254C>T	TOPMed
rs770217072	p.Arg151Trp	missense variant	-	NC_000013.11:g.80337255G>A	ExAC,TOPMed,gnomAD
rs770217072	p.Arg151Trp	missense variant	-	NC_000013.11:g.80337255G>A	NCI-TCGA,NCI-TCGA Cosmic
rs35327895	p.Val152Ala	missense variant	-	NC_000013.11:g.80337251A>G	gnomAD
rs1427241781	p.Pro154His	missense variant	-	NC_000013.11:g.80337245G>T	gnomAD
rs764325903	p.Lys155Gln	missense variant	-	NC_000013.11:g.80337243T>G	ExAC,gnomAD
rs1408015996	p.Leu158Ile	missense variant	-	NC_000013.11:g.80337234G>T	TOPMed
rs575635189	p.Leu163Phe	missense variant	-	NC_000013.11:g.80337219G>A	1000Genomes,ExAC,gnomAD
COSM948814	p.Pro165Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337213G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Glu169Lys	missense variant	-	NC_000013.11:g.80337201C>T	NCI-TCGA
rs1355075892	p.Glu169Val	missense variant	-	NC_000013.11:g.80337200T>A	TOPMed
rs1270955592	p.Leu171Trp	missense variant	-	NC_000013.11:g.80337194A>C	gnomAD
rs765654053	p.Gly172Cys	missense variant	-	NC_000013.11:g.80337192C>A	ExAC,gnomAD
rs765654053	p.Gly172Cys	missense variant	-	NC_000013.11:g.80337192C>A	NCI-TCGA,NCI-TCGA Cosmic
rs572406337	p.Ala175Thr	missense variant	-	NC_000013.11:g.80337183C>T	TOPMed
rs767076954	p.Tyr176Asn	missense variant	-	NC_000013.11:g.80337180A>T	ExAC,gnomAD
rs554006225	p.Arg177Ser	missense variant	-	NC_000013.11:g.80337175C>A	gnomAD
rs761596736	p.Gly182Asp	missense variant	-	NC_000013.11:g.80337161C>T	ExAC,gnomAD
rs1324785933	p.Lys185Arg	missense variant	-	NC_000013.11:g.80337152T>C	TOPMed,gnomAD
rs1324785933	p.Lys185Thr	missense variant	-	NC_000013.11:g.80337152T>G	TOPMed,gnomAD
rs773723743	p.Glu188Gly	missense variant	-	NC_000013.11:g.80337143T>C	ExAC,TOPMed,gnomAD
COSM6139560	p.Tyr191Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337134T>A	NCI-TCGA Cosmic
COSM948812	p.Arg193Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337128C>A	NCI-TCGA Cosmic
rs749195415	p.Pro194Leu	missense variant	-	NC_000013.11:g.80337125G>A	ExAC,TOPMed,gnomAD
rs749195415	p.Pro194Arg	missense variant	-	NC_000013.11:g.80337125G>C	ExAC,TOPMed,gnomAD
rs769531251	p.Asp198His	missense variant	-	NC_000013.11:g.80337114C>G	ExAC,gnomAD
rs745663741	p.Trp199Ser	missense variant	-	NC_000013.11:g.80337110C>G	ExAC,gnomAD
rs745663741	p.Trp199Ter	stop gained	-	NC_000013.11:g.80337110C>T	ExAC,gnomAD
NCI-TCGA novel	p.Cys201AlaPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.80337106G>-	NCI-TCGA
rs771563312	p.Asp202Asn	missense variant	-	NC_000013.11:g.80337102C>T	ExAC,TOPMed,gnomAD
rs747303716	p.Lys203Arg	missense variant	-	NC_000013.11:g.80337098T>C	ExAC,gnomAD
rs1257428671	p.Cys205Ser	missense variant	-	NC_000013.11:g.80337092C>G	TOPMed
rs777966595	p.Leu206Phe	missense variant	-	NC_000013.11:g.80337090G>A	ExAC,TOPMed,gnomAD
rs150929865	p.Asp214Glu	missense variant	-	NC_000013.11:g.80337064G>C	ESP,ExAC,TOPMed,gnomAD
COSM948810	p.Asp214Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80337065T>C	NCI-TCGA Cosmic
rs755298994	p.Tyr215Cys	missense variant	-	NC_000013.11:g.80337062T>C	ExAC,gnomAD
rs766828965	p.Val219Ala	missense variant	-	NC_000013.11:g.80337050A>G	ExAC,gnomAD
NCI-TCGA novel	p.Cys221Tyr	missense variant	-	NC_000013.11:g.80337044C>T	NCI-TCGA
rs751254982	p.Gly224Ser	missense variant	-	NC_000013.11:g.80337036C>T	ExAC,gnomAD
NCI-TCGA novel	p.Phe226Leu	missense variant	-	NC_000013.11:g.80337030A>G	NCI-TCGA
NCI-TCGA novel	p.His228Asp	missense variant	-	NC_000013.11:g.80337024G>C	NCI-TCGA
rs573193459	p.Asp233Glu	missense variant	-	NC_000013.11:g.80337007A>C	1000Genomes,ExAC,gnomAD
rs1272944733	p.Asp239Glu	missense variant	-	NC_000013.11:g.80336989G>C	TOPMed,gnomAD
rs775349105	p.Asn240Ser	missense variant	-	NC_000013.11:g.80336987T>C	ExAC,gnomAD
rs1171758198	p.Cys242Tyr	missense variant	-	NC_000013.11:g.80336981C>T	TOPMed
NCI-TCGA novel	p.Cys244Ter	stop gained	-	NC_000013.11:g.80336974G>T	NCI-TCGA
NCI-TCGA novel	p.Gln246His	missense variant	-	NC_000013.11:g.80336968C>A	NCI-TCGA
rs1452884347	p.His248Pro	missense variant	-	NC_000013.11:g.80336963T>G	gnomAD
NCI-TCGA novel	p.His248Gln	missense variant	-	NC_000013.11:g.80336962G>C	NCI-TCGA
COSM469588	p.Cys249Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.80336960C>T	NCI-TCGA Cosmic
rs1161275655	p.Trp253Leu	missense variant	-	NC_000013.11:g.80336948C>A	gnomAD
rs1335539836	p.Met256Leu	missense variant	-	NC_000013.11:g.80336940T>A	TOPMed
rs776268097	p.Val258Ile	missense variant	-	NC_000013.11:g.80336934C>T	ExAC,gnomAD
rs1383507887	p.Met259Val	missense variant	-	NC_000013.11:g.80336931T>C	gnomAD
rs1183175721	p.Leu263Phe	missense variant	-	NC_000013.11:g.80336917C>G	gnomAD
NCI-TCGA novel	p.Cys265Ter	stop gained	-	NC_000013.11:g.80336912_80336913insTTT	NCI-TCGA
rs770798214	p.Cys268Gly	missense variant	-	NC_000013.11:g.80336904A>C	ExAC,gnomAD
rs1203763232	p.Ala272Ser	missense variant	-	NC_000013.11:g.80336892C>A	gnomAD
rs747157293	p.Lys273Arg	missense variant	-	NC_000013.11:g.80336888T>C	ExAC,gnomAD
rs370842722	p.Gly274Cys	missense variant	-	NC_000013.11:g.80336886C>A	ESP,ExAC,TOPMed,gnomAD
rs1244855227	p.Cys275Tyr	missense variant	-	NC_000013.11:g.80336882C>T	TOPMed,gnomAD
rs79066821	p.Gly281Glu	missense variant	-	NC_000013.11:g.80336864C>T	ExAC,TOPMed,gnomAD
rs79066821	p.Gly281Val	missense variant	-	NC_000013.11:g.80336864C>A	ExAC,TOPMed,gnomAD
rs748239106	p.Arg285Gly	missense variant	-	NC_000013.11:g.80336853G>C	ExAC,TOPMed,gnomAD
rs779197678	p.Arg285Gln	missense variant	-	NC_000013.11:g.80336852C>T	ExAC,TOPMed,gnomAD
rs748239106	p.Arg285Trp	missense variant	-	NC_000013.11:g.80336853G>A	ExAC,TOPMed,gnomAD
rs1384547834	p.Asn287Lys	missense variant	-	NC_000013.11:g.80336845G>C	gnomAD
NCI-TCGA novel	p.Cys291Arg	missense variant	-	NC_000013.11:g.80336835A>G	NCI-TCGA
rs1451158201	p.Arg292His	missense variant	-	NC_000013.11:g.80336831C>T	TOPMed
rs751166788	p.Arg292Cys	missense variant	-	NC_000013.11:g.80336832G>A	ExAC,TOPMed,gnomAD
rs751166788	p.Arg292Cys	missense variant	-	NC_000013.11:g.80336832G>A	NCI-TCGA,NCI-TCGA Cosmic
rs1363735546	p.Cys293Arg	missense variant	-	NC_000013.11:g.80336829A>G	gnomAD
NCI-TCGA novel	p.Lys294Thr	missense variant	-	NC_000013.11:g.80336825T>G	NCI-TCGA
NCI-TCGA novel	p.Lys294Glu	missense variant	-	NC_000013.11:g.80336826T>C	NCI-TCGA
rs1191449743	p.Asn295His	missense variant	-	NC_000013.11:g.80336823T>G	TOPMed
rs763750552	p.Asn295Ser	missense variant	-	NC_000013.11:g.80336822T>C	ExAC
NCI-TCGA novel	p.Ser296Ter	stop gained	-	NC_000013.11:g.80336819G>C	NCI-TCGA
rs1163020327	p.Asn297Tyr	missense variant	-	NC_000013.11:g.80336817T>A	gnomAD
NCI-TCGA novel	p.Asn297GlnPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.80336814_80336817TGTT>-	NCI-TCGA
NCI-TCGA novel	p.Asn297Thr	missense variant	-	NC_000013.11:g.80336816T>G	NCI-TCGA
rs1425467478	p.Thr298Ser	missense variant	-	NC_000013.11:g.80336814T>A	gnomAD
rs762383535	p.Val299Ala	missense variant	-	NC_000013.11:g.80336810A>G	ExAC,gnomAD
rs752200065	p.Cys301Tyr	missense variant	-	NC_000013.11:g.80336804C>T	ExAC,gnomAD
rs1262917592	p.Thr305Asn	missense variant	-	NC_000013.11:g.80336792G>T	gnomAD
rs1262917592	p.Thr305Ser	missense variant	-	NC_000013.11:g.80336792G>C	gnomAD
rs759359294	p.Val306Ile	missense variant	-	NC_000013.11:g.80336790C>T	ExAC,gnomAD
NCI-TCGA novel	p.Val306Ala	missense variant	-	NC_000013.11:g.80336789A>G	NCI-TCGA
rs766036986	p.Pro307Thr	missense variant	-	NC_000013.11:g.80336787G>T	ExAC,gnomAD
rs760529490	p.Pro307Arg	missense variant	-	NC_000013.11:g.80336786G>C	ExAC,TOPMed,gnomAD
rs760529490	p.Pro307Leu	missense variant	-	NC_000013.11:g.80336786G>A	ExAC,TOPMed,gnomAD
rs981467157	p.Pro308Ala	missense variant	-	NC_000013.11:g.80336784G>C	TOPMed,gnomAD
rs981467157	p.Pro308Ser	missense variant	-	NC_000013.11:g.80336784G>A	TOPMed,gnomAD
NCI-TCGA novel	p.Pro308LeuPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.80336783G>-	NCI-TCGA
rs748443333	p.Glu312Gly	missense variant	-	NC_000013.11:g.80336771T>C	ExAC,gnomAD
NCI-TCGA novel	p.Lys313AsnPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.80336767T>-	NCI-TCGA
rs1425368251	p.Ter316Leu	stop lost	-	NC_000013.11:g.80336759T>A	gnomAD
rs987689192	p.Ter316Gln	stop lost	-	NC_000013.11:g.80336760A>G	TOPMed,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0003864	Arthritis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007222	Cardiovascular Diseases	group	BEFREE
C0008924	Cleft upper lip	disease	CTD_human
C0008925	Cleft Palate	disease	CTD_human
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE
C0014145	Yolk Sac Tumor	disease	BEFREE
C0014848	Esophageal Achalasia	disease	MGD
C0016057	Fibrosarcoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0017661	IGA Glomerulonephritis	disease	BEFREE;CTD_human
C0023890	Liver Cirrhosis	disease	BEFREE
C0024115	Lung diseases	group	CTD_human
C0024121	Lung Neoplasms	group	CTD_human
C0024299	Lymphoma	group	BEFREE
C0024305	Lymphoma, Non-Hodgkin	disease	LHGDN
C0025202	melanoma	disease	BEFREE;LHGDN
C0027819	Neuroblastoma	group	LHGDN
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0033578	Prostatic Neoplasms	group	LHGDN
C0036631	Seminoma	disease	BEFREE
C0079731	B-Cell Lymphomas	group	BEFREE
C0220748	Cartilage-hair hypoplasia	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE;CTD_human
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0281361	Adenocarcinoma of pancreas	disease	BEFREE
C0345904	Malignant neoplasm of liver	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0376544	Hematopoietic Neoplasms	group	BEFREE
C0376634	Craniofacial Abnormalities	group	CTD_human
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1832589	Neuronal Intestinal Dysplasia, Type B	disease	MGD
C1837218	Cleft palate, isolated	disease	CTD_human
C1855733	Neuronal intestinal pseudoobstruction	disease	MGD
C2239176	Liver carcinoma	disease	BEFREE;LHGDN
C3714542	Lymphoma, Diffuse	disease	BEFREE
C4225194	IgA NEPHROPATHY, SUSCEPTIBILITY TO, 3	phenotype	CLINVAR;UNIPROT

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005515	protein binding	IPI
GO:0019901	protein kinase binding	IPI
GO:0030291	protein serine/threonine kinase inhibitor activity	IC
GO:0043539	protein serine/threonine kinase activator activity	IMP

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000132	establishment of mitotic spindle orientation	IEA
GO:0007605	sensory perception of sound	IEA
GO:0008285	negative regulation of cell population proliferation	IEA
GO:0010628	positive regulation of gene expression	IMP
GO:0010801	negative regulation of peptidyl-threonine phosphorylation	IDA
GO:0016525	negative regulation of angiogenesis	IMP
GO:0030335	positive regulation of cell migration	IMP
GO:0031345	negative regulation of cell projection organization	ISS
GO:0033138	positive regulation of peptidyl-serine phosphorylation	IMP
GO:0034260	negative regulation of GTPase activity	IEA
GO:0035924	cellular response to vascular endothelial growth factor stimulus	IDA
GO:0040037	negative regulation of fibroblast growth factor receptor signaling pathway	IBA
GO:0042059	negative regulation of epidermal growth factor receptor signaling pathway	TAS
GO:0042472	inner ear morphogenesis	IEA
GO:0043066	negative regulation of apoptotic process	IMP
GO:0043407	negative regulation of MAP kinase activity	IBA
GO:0045165	cell fate commitment	IEA
GO:0045595	regulation of cell differentiation	IEA
GO:0046580	negative regulation of Ras protein signal transduction	IBA
GO:0048513	animal organ development	IBA
GO:0051387	negative regulation of neurotrophin TRK receptor signaling pathway	IEA
GO:0051897	positive regulation of protein kinase B signaling	IMP
GO:0060437	lung growth	IEA
GO:0060449	bud elongation involved in lung branching	IEA
GO:0070373	negative regulation of ERK1 and ERK2 cascade	ISS
GO:0070373	negative regulation of ERK1 and ERK2 cascade	IMP
GO:0070373	negative regulation of ERK1 and ERK2 cascade	IDA
GO:0070374	positive regulation of ERK1 and ERK2 cascade	IMP
GO:0071902	positive regulation of protein serine/threonine kinase activity	IEA
GO:1900747	negative regulation of vascular endothelial growth factor signaling pathway	IDA
GO:1990830	cellular response to leukemia inhibitory factor	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005623	cell	IEA
GO:0005634	nucleus	ISS
GO:0005829	cytosol	ISS
GO:0005829	cytosol	IBA
GO:0005829	cytosol	TAS
GO:0005856	cytoskeleton	ISS
GO:0005886	plasma membrane	TAS
GO:0015629	actin cytoskeleton	IDA
GO:0015630	microtubule cytoskeleton	IDA
GO:0016020	membrane	ISS
GO:0032587	ruffle membrane	IEA
GO:1990752	microtubule end	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1295596	Spry regulation of FGF signaling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-177929	Signaling by EGFR	TAS
R-HSA-182971	EGFR downregulation	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-5654726	Negative regulation of FGFR1 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654732	Negative regulation of FGFR3 signaling	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRY2 mRNA	28329830
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of SPRY2 mRNA	19095052
C434003	3-(4-methylphenylsulfonyl)-2-propenenitrile	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [nickel chloride results in decreased expression of SPRY2 protein]	26026961
C088860	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [nickel chloride results in decreased expression of SPRY2 protein]	26026961
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane results in decreased expression of SPRY2 mRNA	18648102
C517041	(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in decreased expression of SPRY2 mRNA	19561079
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of SPRY2 mRNA	12419474
D015124	8-Bromo Cyclic Adenosine Monophosphate	8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRY2 mRNA	22079614
D015127	9,10-Dimethyl-1,2-benzanthracene	[chlorophyllin co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of SPRY2 mRNA	22485181
C496492	abrine	abrine results in increased expression of SPRY2 mRNA	31054353
D000079	Acetaldehyde	Acetaldehyde affects the expression of SPRY2 mRNA	22634333
D000082	Acetaminophen	Acetaminophen results in increased expression of SPRY2 mRNA	26690555; 29067470;
D000082	Acetaminophen	Acetaminophen affects the expression of SPRY2 mRNA	17562736
D001151	Arsenic	Arsenic affects the methylation of SPRY2 gene	25304211
C015001	arsenite	arsenite results in decreased expression of SPRY2 protein	22387281
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite affects the expression of SPRY2 mRNA	25757056
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of SPRY2 mRNA	18687144
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased methylation of SPRY2 gene	29523930
D001280	Atrazine	Atrazine results in decreased expression of SPRY2 mRNA	22378314
C044887	beta-methylcholine	beta-methylcholine affects the expression of SPRY2 mRNA	21179406
C006780	bisphenol A	bisphenol A affects the expression of SPRY2 mRNA	20170705
C006780	bisphenol A	bisphenol A results in decreased expression of SPRY2 mRNA	29275510
C006780	bisphenol A	bisphenol A affects the expression of SPRY2 mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of SPRY2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased expression of SPRY2 mRNA	30816183
C006780	bisphenol A	bisphenol A results in increased methylation of SPRY2 gene	28505145
C584509	C646 compound	C646 compound results in decreased expression of SPRY2 mRNA	26191083
D002117	Calcitriol	Calcitriol results in increased expression of SPRY2 mRNA	16002434
D002220	Carbamazepine	Carbamazepine affects the expression of SPRY2 mRNA	22634333
C007020	chlorophyllin	[chlorophyllin co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of SPRY2 mRNA	22485181
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of SPRY2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of SPRY2 mRNA	27392435
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of SPRY2 mRNA	19320972
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of SPRY2 mRNA	19549813
D016572	Cyclosporine	Cyclosporine results in increased expression of SPRY2 mRNA	20106945
C093628	cyproconazole	cyproconazole results in decreased expression of SPRY2 mRNA	22045034
D000069439	Dasatinib	Dasatinib results in decreased expression of SPRY2 mRNA	20579391
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of SPRY2 mRNA	17361019; 21266533;
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of SPRY2 mRNA	21266533
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of SPRY2 mRNA	26924002
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of SPRY2 mRNA	24535843
C472787	erucylphospho-N,N,N-trimethylpropylammonium	erucylphospho-N,N,N-trimethylpropylammonium results in increased expression of SPRY2 mRNA	29464035
D000431	Ethanol	Ethanol affects the expression of SPRY2 mRNA	30319688
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in decreased expression of SPRY2 mRNA	23649840
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRY2 mRNA	28329830
D005473	Fluoxetine	Fluoxetine affects the expression of SPRY2 mRNA	29893963
C061365	flusilazole	flusilazole affects the expression of SPRY2 mRNA	22634333
D005557	Formaldehyde	Formaldehyde results in decreased expression of SPRY2 mRNA	20655997
C039281	furan	furan results in increased expression of SPRY2 mRNA	27387713
D005742	Gasoline	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA	29432896
C063170	Ginkgo biloba extract	Ginkgo biloba extract results in increased methylation of SPRY2 promoter	31278416
D005947	Glucose	Glucose results in increased expression of SPRY2 mRNA	17178593
C000593030	GSK-J4	GSK-J4 results in increased expression of SPRY2 mRNA	29301935
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of SPRY2 mRNA	20044591
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased expression of SPRY2 mRNA	12419474
C545476	incobotulinumtoxinA	incobotulinumtoxinA results in decreased expression of SPRY2 mRNA	29522793
C040507	isobutyl alcohol	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA	29432896
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of SPRY2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of SPRY2 mRNA	24796395
C561695	(+)-JQ1 compound	[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA	25119042
C008261	lead acetate	lead acetate results in decreased expression of SPRY2 mRNA	22609695
D000077339	Leflunomide	Leflunomide results in increased expression of SPRY2 mRNA	28988120
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of SPRY2 mRNA	26378955
D008694	Methamphetamine	Methamphetamine results in increased expression of SPRY2 mRNA	29802913
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of SPRY2 mRNA	20713471
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of SPRY2 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of SPRY2 mRNA	23649840
D008770	Methylnitrosourea	Methylnitrosourea results in increased expression of SPRY2 mRNA	17412507
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of SPRY2 mRNA	26924002
C500085	muraglitazar	muraglitazar results in decreased expression of SPRY2 mRNA	21515302
D009532	Nickel	Nickel results in decreased expression of SPRY2 mRNA	20881000
D009532	Nickel	Nickel results in decreased expression of SPRY2 protein	20881000
D009532	Nickel	SPRY2 mRNA affects the reaction [Nickel results in increased phosphorylation of MAPK1 protein]	20881000
D009532	Nickel	SPRY2 mRNA affects the reaction [Nickel results in increased phosphorylation of MAPK3 protein]	20881000
D009532	Nickel	SPRY2 protein inhibits the reaction [Nickel results in increased phosphorylation of MAPK1 protein]	20881000
D009532	Nickel	SPRY2 protein inhibits the reaction [Nickel results in increased phosphorylation of MAPK3 protein]	20881000
C022838	nickel chloride	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [nickel chloride results in decreased expression of SPRY2 protein]	26026961
C022838	nickel chloride	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [nickel chloride results in decreased expression of SPRY2 protein]	26026961
C022838	nickel chloride	nickel chloride results in decreased expression of SPRY2 protein	26026961
C022838	nickel chloride	[nickel chloride results in increased expression of MIR21 mRNA] which results in decreased expression of SPRY2 protein	26026961
C007350	nitrofen	nitrofen results in decreased expression of and results in decreased phosphorylation of SPRY2 protein	24210189
C007350	nitrofen	nitrofen results in decreased expression of SPRY2 mRNA	23982388; 24210189;
C570897	NSC668394	NSC668394 results in increased expression of SPRY2 mRNA	27137931
D010100	Oxygen	Oxygen deficiency promotes the reaction [KDM3A protein binds to SPRY2 promoter]	20881000
D010100	Oxygen	Oxygen deficiency results in decreased expression of SPRY2 mRNA	20881000
D010100	Oxygen	Oxygen deficiency results in decreased expression of SPRY2 protein	20881000
D052638	Particulate Matter	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA	29432896
D052638	Particulate Matter	Particulate Matter results in increased expression of SPRY2 mRNA	29703138
C506614	PD 0325901	[PD 0325901 co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA	25119042
C506614	PD 0325901	PD 0325901 results in decreased expression of SPRY2 mRNA	25119042
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether analog results in increased expression of SPRY2 mRNA	19095052
D010634	Phenobarbital	Phenobarbital affects the expression of SPRY2 mRNA	19159669
C018637	phorone	phorone affects the expression of SPRY2 mRNA	18198479
C006253	pirinixic acid	pirinixic acid results in increased expression of SPRY2 mRNA	17426115
D010938	Plant Oils	Plant Oils results in increased expression of SPRY2 mRNA	23370395
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA	29432896
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of SPRY2 mRNA	22714537
C513635	S-2-pentyl-4-pentynoic hydroxamic acid	S-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of SPRY2 mRNA	21427059
D012834	Silver	Silver results in decreased expression of SPRY2 mRNA	27131904
C017947	sodium arsenite	sodium arsenite results in decreased expression of SPRY2 mRNA	29361514
C017947	sodium arsenite	sodium arsenite results in decreased expression of SPRY2 mRNA	19072884
D012999	Soman	Soman results in increased expression of SPRY2 mRNA	19281266
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of SPRY2 mRNA	26378955
D000077210	Sunitinib	Sunitinib results in increased expression of SPRY2 mRNA	31533062
C061133	tamibarotene	tamibarotene results in increased expression of SPRY2 mRNA	15498508
D013629	Tamoxifen	Tamoxifen affects the expression of SPRY2 mRNA	20937368
D013654	Taurine	Taurine results in increased expression of SPRY2 mRNA	16579726
C501413	tesaglitazar	tesaglitazar results in decreased expression of SPRY2 mRNA	21515302
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to SPRY2 promoter]	19654925
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SPRY2 mRNA	21215274
D019284	Thapsigargin	Thapsigargin results in decreased expression of SPRY2 mRNA	22378314
C483909	torcetrapib	torcetrapib results in increased expression of SPRY2 mRNA	23228038
D014212	Tretinoin	Tretinoin affects the expression of SPRY2 mRNA	15498508
D014212	Tretinoin	Tretinoin results in decreased expression of SPRY2 mRNA	23724009
C012589	trichostatin A	trichostatin A results in decreased expression of SPRY2 mRNA	26272509
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of SPRY2 mRNA	19042947
D014415	Tunicamycin	Tunicamycin results in decreased expression of SPRY2 mRNA	22378314; 29453283;
D014520	Urethane	Urethane results in increased expression of SPRY2 mRNA	28818685
D014635	Valproic Acid	Valproic Acid affects the expression of SPRY2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of SPRY2 mRNA	23179753; 25192806; 27188386;
D014635	Valproic Acid	Valproic Acid results in increased expression of SPRY2 mRNA	24935251; 28001369;
D014635	Valproic Acid	Valproic Acid results in decreased expression of SPRY2 mRNA	21427059; 22045034;
D000068756	Valsartan	Valsartan inhibits the reaction [AGT protein results in increased expression of SPRY2 mRNA]	19225232
D014638	Vanadates	Vanadates results in increased expression of SPRY2 mRNA	22714537
C025643	vinclozolin	vinclozolin results in increased expression of SPRY2 mRNA	23034163
D024483	Vitamin K 3	Vitamin K 3 affects the expression of SPRY2 mRNA	20044591
D024483	Vitamin K 3	Vitamin K 3 results in decreased expression of SPRY2 mRNA	25270620
D000077337	Vorinostat	Vorinostat results in decreased expression of SPRY2 mRNA	27188386

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-1003	Cell membrane
KW-0966	Cell projection
KW-0963	Cytoplasm
KW-0206	Cytoskeleton
KW-0217	Developmental protein
KW-0225	Disease mutation
KW-0472	Membrane
KW-0493	Microtubule
KW-0621	Polymorphism
KW-1185	Reference proteome

Interpro

InterPro ID	InterPro Term
IPR007875	Sprouty
IPR030780	SPRY2

PROSITE

PROSITE ID	PROSITE Term
PS51227	SPR

Pfam

Pfam ID	Pfam Term
PF05210	Sprouty

Gene: SPRY2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction